Corona Remedies Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹13,561 Cr
- P/E
- 64.03
- ROE
- 29.53%
- PEG
- 1.94
- Price to sales
- 9.17
- Debt to equity
- 0.22
- 52W high / low
- ₹2,236 / ₹1,348
- Sales growth (5Y)
- 19.49%
- EBITDA margin
- 21.42%
- Net profit margin
- 14.22%
- Promoter holding
- 69.00%
- Sales (last year)
- ₹1,479 Cr
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]
Guidance scorecard · Q1 FY27 call
What Corona Remedies Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- CORONA Remedies targets 15% organic revenue growth for FY27, with an additional 25% growth expected from inorganic opportunities, totaling about 17% revenue growth overall.
- The company aims to sustain double-digit industry growth, anticipating Indian Pharmaceutical Market (IPM) growth around 9%-11% annually.
- Volume growth significantly outpaces the IPM, with 6.3% volume growth versus 1.3% for the IPM in MAT June 2026 (approx. 5x IPM).
- Price-led growth and new product introductions also contribute, with prices growing at 8.7% versus IPM’s 5.6%, and new product introductions at 3.4% versus IPM’s 2.9%.
- Strong ramp-up expected in IVF business over next 2-3 quarters as the MR taskforce scales efforts.
2 more points from Corona Remedies Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Corona Remedies Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Corona Remedies Limited has recently commissioned a new EU GMP approved hormonal manufacturing plant with a capex of INR 130 crores.
- The hormonal plant started operations on June 30, 2026, and is expected to have an asset turnover of less than 1x in FY27, gradually increasing to 2-3x over the next three years.
- The company is in the final stages of preparing dossiers for this plant to enable international market entry, targeting FY28-29 for international scale-up.
- Additional capital investments related to brand acquisitions include the Wokadine brand (acquired for INR 97 crores plus GST), amortized over 10 years, and a Bayer brand acquired for INR 7 crores.
FundraisingQ1 FY27 call
See what Corona Remedies Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Ask what Corona Remedies Ltd said on the order book →
Full Q1 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Corona Remedies Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Corona Remedies Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Corona Remedies Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 314 | 298 | 294 | 347 | 361 | 342 | 353 |
| Expenses + | 247 | 228 | 239 | 277 | 283 | 259 | 291 |
| Operating Profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 |
| OPM % | 21% | 23% | 18% | 20% | 22% | 24% | 18% |
| Other Income + | 2 | 1 | 1 | 2 | 2 | -17 | 4 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 |
| Profit before tax | 57 | 58 | 43 | 61 | 70 | 55 | 54 |
| Tax % | 25% | 23% | 28% | 24% | 25% | 25% | 17% |
| Net Profit + | 43 | 45 | 31 | 46 | 52 | 41 | 45 |
| EPS in Rs | 7.03 | 7.32 | 5.12 | 7.59 | 8.53 | 6.74 | 7.37 |
Financials of Corona Remedies Ltd
Profit & Loss
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 509 | 601 | 576 | 617 | 884 | 1,014 | 1,196 | 1,403 |
| Expenses + | 444 | 509 | 471 | 600 | 756 | 859 | 956 | 1,110 |
| Operating Profit | 66 | 93 | 105 | 18 | 128 | 156 | 241 | 293 |
| OPM % | 13% | 15% | 18% | 3% | 14% | 15% | 20% | 21% |
| Other Income + | 3 | 3 | 5 | 7 | 7 | 5 | 5 | -8 |
| Interest | 1 | 2 | 2 | 5 | 4 | 14 | 11 | 7 |
| Depreciation | 14 | 16 | 16 | 20 | 20 | 28 | 37 | 38 |
| Profit before tax | 54 | 77 | 92 | -1 | 111 | 118 | 198 | 240 |
| Tax % | 35% | 24% | 24% | -49% | 23% | 24% | 25% | 23% |
| Net Profit + | 35 | 59 | 70 | -0 | 85 | 90 | 149 | 185 |
| EPS in Rs | 74.85 | 126.70 | 150.72 | -0.08 | 13.85 | 14.80 | 24.37 | 30.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 20% | 25% | 30% | 0% |
Financials of Corona Remedies Ltd
Balance Sheet
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 51 | 61 | 61 | 61 | 61 |
| Reserves | 204 | 263 | 333 | 270 | 347 | 419 | 545 | 685 |
| Borrowings + | 13 | 47 | 50 | 34 | 28 | 159 | 86 | 165 |
| Other Liabilities + | 71 | 94 | 144 | 157 | 159 | 191 | 237 | 293 |
| Total Liabilities | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
| Fixed Assets + | 80 | 81 | 164 | 162 | 185 | 384 | 370 | 554 |
| CWIP | 4 | 42 | 0 | 14 | 65 | 121 | 186 | 143 |
| Investments | 9 | 7 | 37 | 14 | 31 | 25 | 25 | 25 |
| Other Assets + | 200 | 278 | 330 | 321 | 314 | 301 | 348 | 482 |
| Total Assets | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
Financials of Corona Remedies Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 19 | 43 | 79 | 98 | 103 | 157 | 190 | 229 |
| Cash from Investing Activity + | -23 | -50 | -102 | -66 | -50 | -267 | -84 | -256 |
| Cash from Financing Activity + | 4 | 30 | 0 | -30 | -45 | 99 | -107 | 25 |
| Net Cash Flow | -1 | 23 | -23 | 2 | 8 | -11 | 0 | -1 |
| Free Cash Flow | 19 | 1 | 6 | 64 | 9 | -129 | 99 | 55 |
| CFO/OP | 49% | 65% | 101% | 557% | 100% | 112% | 97% | 95% |
Financials of Corona Remedies Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 105 | 131 | 44 | 36 | 36 | 36 | 38 |
| Inventory Days | 69 | 52 | 77 | 184 | 182 | 158 | 200 | 175 |
| Days Payable | 126 | 110 | 182 | 211 | 163 | 184 | 221 | 206 |
| Cash Conversion Cycle | 38 | 48 | 27 | 17 | 55 | 10 | 14 | 7 |
| Working Capital Days | 67 | 81 | 86 | 16 | 30 | -2 | 9 | -15 |
| ROCE % | 30% | 27% | 1% | 29% | 25% | 31% | 33% |
Guidance history
How Corona Remedies Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q3 FY26 call → | 10–20% | Flat | Planned | None planned | — |
| Q3 FY26 call → | 10–20% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Corona Remedies Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY